News

Filter

1 to 9 of 31 results

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

23-12-2014

The US Food and Drug Administration yesterday granted accelerated approval to US pharma major Bristol-Myers…

Bristol-Myers SquibbKeytrudaMerck & CoOncologyOpdivoPharmaceuticalRegulationUSA

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Bristol-Myers resolves Sustiva patent litigation in USA

Bristol-Myers resolves Sustiva patent litigation in USA

08-10-2014

US pharma major Bristol-Myers Squibb has successfully resolved all outstanding US patent litigation relating…

Anti-viralsAtriplaBristol-Myers SquibbCiplaLegalMerck & CoPatentsPharmaceuticalSustivaUSA

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

30-09-2014

Early results from pharma giant Merck & Co on the use of its Keytruda (pembrolizumab) in patients with…

BiotechnologyBristol-Myers SquibbKeytrudaMerck & CoMerck Research LaboratoriesOncologyOpdivoResearchSpain

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

08-09-2014

US drug major Bristol-Myers Squibb and partner Japan’s Ono Pharmaceutical have filed a law suit against…

Advanced melanomaBristol-Myers SquibbIpilimumabKeytrudaLaw suitLegalMerck & CoOncologyOno PharmaceuticalPharmaceuticalUSA

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

01-07-2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1…

AstraZenecaBristol-Myers SquibbEuropeJapanMarkets & MarketingMED14736Merck & ConivolumabOncologypembrolizumabPharmaceuticalResearchRocheUSAYervoy

1 to 9 of 31 results

COMPANY SPOTLIGHT

Menarini

Back to top